Randomized, Double‐Blind Comparative Trial of Subunit and Virosomal Influenza Vaccines for Immunocompromised Patients

Evison, John; Farese, Stefan; Seitz, Michael; Uehlinger, Dominik E.; Furrer, Hansjakob; Mühlemann, Kathrin

doi:10.1086/598193

Cited by 72 publications

(38 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The rate and intensity of reported solicited local and systemic reactions to vaccination were similar in patients and controls and were in accordance with safety outcomes reported in other studies using virosomal influenza vaccines (de Bruijn et al, 2005;Evison et al, 2009;Kunzi et al, 2009). In the suspicion that cKS patients may be more prone to autoimmunity than controls because of expansion of transitional and other preimmune B cells that are endowed with high autoimmune potential (Della Bella et al, 2010;Varin et al, 2010), we measured ANAs in their serum.…”

Section: Discussionsupporting

confidence: 85%

Immunogenicity and Safety of Seasonal Influenza Vaccination in Patients with Classic Kaposi's Sarcoma

Cappelletti

Taddeo

Colombo

et al. 2012

Journal of Investigative Dermatology

View full text Add to dashboard Cite

Classic Kaposi's sarcoma (cKS) is a human herpesvirus-8 (HHV-8)-associated lympho-angioproliferative tumor typically occurring in the elderly. It is associated with HHV-8-driven perturbed balance of peripheral B-cell subsets, which may have an impact on immune responses to antigenic stimulation. We took advantage of the common practice of cKS patients to undergo seasonal influenza vaccination because of advanced age and analyzed the immunogenicity and safety of licensed trivalent influenza vaccine in 46 cKS patients and 44 matched controls. Licensure criteria for immunogenicity were fulfilled in both groups. Four weeks after vaccination, hemagglutination-inhibition antibody titers against each viral strain contained in the vaccine increased in patients and controls (all P<0.001). Protection against at least one strain was achieved by 96% of cKS and 91% of control subjects. Protection against all strains persisted after 12 weeks, demonstrating a long-lasting response to vaccination. The vaccine was equally well tolerated by patients and controls, as assessed by evaluating solicited local and systemic reactions to the vaccine, and appearance or increase of antinuclear autoantibodies. HHV-8 virological rebound was observed in four cKS patients, but was not accompanied by progression of KS lesions. We conclude that seasonal influenza vaccine given to cKS patients is immunogenic and safe.

show abstract

Section: Discussionsupporting

confidence: 85%

Immunogenicity and Safety of Seasonal Influenza Vaccination in Patients with Classic Kaposi's Sarcoma

Cappelletti

Taddeo

Colombo

et al. 2012

Journal of Investigative Dermatology

View full text Add to dashboard Cite

show abstract

“…Despite a high mean CD4 cell count of all patients included in our study (514 AE 246 cells/ml), higher CD4 cell count was associated with seroconversion (P ¼ 0.03), whereas previous AIDS or a low CD4 nadir was not. Two more recent studies showed vaccine response of the seasonal influenza vaccination to be related to HIV RNA PCR levels [24,25]. The proportion of patients treated with HAART or having a HIV RNA PCR below the limit of detection was higher in the group of seroconverters, but these differences were not statistically significant.…”

Section: Discussionmentioning

confidence: 99%

Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients

Bickel¹,

Wieters²,

Khaykin³

et al. 2010

Aids

View full text Add to dashboard Cite

show abstract

“…Several studies have shown lower antibody responses in HIVinfected persons compared with HIV-uninfected persons after seasonal influenza vaccination, with some suggesting that persons with low CD4 cell counts or AIDS have the most limited antibody response to influenza vaccination [77][78][79][80][81]. However, a few HAART-era studies conducted before the pH1N1 pandemic suggest that immune response may be related to HIV viral load rather than CD4 cell count [82][83][84]. Studies examining protection from clinical influenza post-vaccination, rather than antibody response, suggest that influenza vaccination of HIV-infected adults may be effective despite variable antibody responses [74••, 85], but data on the clinical effectiveness of influenza vaccination in HIV-infected persons are limited.…”

Section: Postexposure Chemoprophylaxis and Ph1n1 Vaccine Among Hiv-inmentioning

confidence: 99%

Influenza and HIV: Lessons from the 2009 H1N1 Influenza Pandemic

2011

View full text Add to dashboard Cite

Influenza is a common respiratory disease in adults, including those infected with HIV. In the spring of 2009, a pandemic influenza A (H1N1) virus (pH1N1) emerged. In this article, we review the existing literature regarding pH1N1 virus infection in HIV-infected adults, which suggests that susceptibility to pH1N1 virus infection and severity of influenza illness are likely not increased in HIV-infected adults without advanced immunosuppression or comorbid conditions. The risk of influenza-related complications, however, may be increased in those with advanced immunosuppression or high-risk comorbid conditions. Prevention and treatment of high-risk comorbid conditions and annual influenza vaccination should continue to be part of HIV clinical care to help prevent influenza illness and complications. Additional information about pH1N1 vaccine immunogenicity and efficacy in HIV-infected patients would be useful to guide strategies to prevent influenza virus infection in this population.

show abstract

Randomized, Double‐Blind Comparative Trial of Subunit and Virosomal Influenza Vaccines for Immunocompromised Patients

Abstract: NCT00783380 .

Cited by 72 publications

References 24 publications

Immunogenicity and Safety of Seasonal Influenza Vaccination in Patients with Classic Kaposi's Sarcoma

Immunogenicity and Safety of Seasonal Influenza Vaccination in Patients with Classic Kaposi's Sarcoma

Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients

Influenza and HIV: Lessons from the 2009 H1N1 Influenza Pandemic

Contact Info

Product

Resources

About